STRATA Skin Sciences Files 8-K
Ticker: SSKN · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1051514
| Field | Detail |
|---|---|
| Company | Strata Skin Sciences, Inc. (SSKN) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
STRATA Skin Sciences filed an 8-K on Aug 7, 2025, with Reg FD disclosures and financial exhibits.
AI Summary
STRATA Skin Sciences, Inc. filed an 8-K on August 7, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as MELA SCIENCES, INC. and ELECTRO OPTICAL SCIENCES INC, is based in Horsham, PA, and operates in the Surgical & Medical Instruments & Apparatus industry.
Why It Matters
This filing indicates that STRATA Skin Sciences, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains disclosures of material events or financial information, but the filing itself does not inherently signal high risk.
Key Numbers
- 000-51481 — SEC File Number (Identifies the company's filing with the SEC.)
- 13-3986004 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- STRATA Skin Sciences, Inc. (company) — Registrant
- MELA SCIENCES, INC. (company) — Former Company Name
- ELECTRO OPTICAL SCIENCES INC (company) — Former Company Name
- August 7, 2025 (date) — Date of Report
- Horsham, Pennsylvania (location) — Principal Executive Offices
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of this disclosure are not provided in the header information.
What types of financial statements and exhibits are included?
The filing states 'Financial Statements and Exhibits' are included, but the specific nature of these documents is not detailed in the header.
When was the company formerly known as MELA SCIENCES, INC.?
The date of name change from MELA SCIENCES, INC. was May 4, 2010.
What is the company's Standard Industrial Classification code?
The SIC code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
Where are STRATA Skin Sciences, Inc.'s principal executive offices located?
The principal executive offices are located at 5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044.
Filing Stats: 794 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2025-08-07 08:30:37
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SSKN The NASDAQ
Filing Documents
- ef20053379_8k.htm (8-K) — 30KB
- ef20053379_ex99-1.htm (EX-99.1) — 17KB
- image0.jpg (GRAPHIC) — 209KB
- 0001140361-25-029355.txt ( ) — 701KB
- sskn-20250807.xsd (EX-101.SCH) — 4KB
- sskn-20250807_lab.xml (EX-101.LAB) — 21KB
- sskn-20250807_pre.xml (EX-101.PRE) — 16KB
- ef20053379_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On August 7, 2025, STRATA Skin Sciences, Inc. (the "Company") issued a press release announcing its work with the Centers for Medicare & Medicaid Services (CMS) to obtain temporary codes that would accelerate access to recently expanded reimbursement for its XTRAC excimer laser treatment. As the Company had previously announced, the American Medical Association's CPT Editorial Panel, in a landmark decision, approved updates to codes 96920–96922, expanding reimbursement eligibility for XTRAC Excimer Laser treatments to include all inflammatory and autoimmune skin conditions—such as vitiligo, atopic dermatitis, and alopecia areata—in addition to psoriasis, effective January 1, 2027. By securing temporary CMS codes, the Company aims to make these expanded indications reimbursable as early as the 2026 rule cycle, effectively tripling the addressable patient population while improving treatment economics for both providers and the Company. The press release also reported on recent peer reviewed publications supporting excimer laser therapy in combination with JAK inhibitors for treating vitiligo. The Company's intellectual property portfolio includes patents for the use of JAK inhibitors in combination with excimer laser therapy. Also covered in the press release is an update on the lawsuit for unfair competition under the Lanham Act against LaserOptek America and other parties. Specifically, the release stated that that the Federal District Court has agreed with the Company's position that LaserOptek Co. Ltd, (LaserOptek Korea') the South Korean parent of LaserOptek America, should be added as a defendant in the lawsuit, and that the Company was encouraged that the court recognized that the Company was justified in its assertions that the US based defendants had engaged in duplicitous actions in attempting to hide and shield the Korean entity from the lawsuit. The court also allowed the Company to add another defendant, C. Dalto
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. The following press release is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be "filed": Exhibit No. Exhibit Description 99.1 Press release dated August 7, 2025, issued by Strata Skin Sciences, Inc. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STRATA SKIN SCIENCES, INC. Date: August 7, 2025 By: /s/ John Gillings John Gillings Chief Accounting Officer